New Guideline for CMD Diagnosis and Care

New Guideline for CMD Diagnosis and Care

A committee convened by the American Academy of Neurology has published new recommendations for doctors who see children with congenital muscular dystrophy

CMD: Phase 1 Omigapil Trial Remains Open

CMD: Phase 1 Omigapil Trial Remains Open

Santhera Pharmaceuticals is testing anti-cell death compound omigapil in children and teens with merosin-deficient and Ullrich congenital muscular dystrophies

FDA OKs Testing of OPMD Drug in US

FDA OKs Testing of OPMD Drug in US

Israel-based BioBlast Pharma says a California site will be added soon to locations already testing Cabaletta in oculopharyngeal muscular dystrophy in Israel and Canada

SMA: ISIS-SMNRx To Be Tested in Presymptomatic Infants

SMA: ISIS-SMNRx To Be Tested in Presymptomatic Infants

The experimental antisense drug will be tested in infants with a genetic spinal muscular atrophy diagnosis who are to date without symptoms

DMD: New Strategy Aims to Change Dystrophin DNA

DMD: New Strategy Aims to Change Dystrophin DNA

MDA-supported researcher Charles Gersbach and colleagues have developed a strategy to change dystrophin DNA that has shown promise in the lab

NIH Will Test Antioxidant Drug in Central Core Disease

NIH Will Test Antioxidant Drug in Central Core Disease

A drug that has FDA approval for other indications is being tested in CCD patients who are at least 7 years old

FEATURED IN QUEST MAGAZINE

Accelerating progress in 2015 — and beyond

posted on January 5, 2015 - 9:01am
MDA’s resolve and action steps to accelerate progress on behalf of our families fighting muscle disease has never been greater. People fighting these difficult diseases are depending on MDA to fulfill our mission to save and improve their lives.  To most effectively help our families, MDA must be very intentional about building on the scientific and medical progress we have led for the past...